LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of $17.00. The company's shares closed last Wednesday at $5.90. According to TipRanks.com, Slutsky is ranked 0 out of 5 stars with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.33 average price target, representing a 169.5% upside. In a report issued on January 25, H.C.
https://www.tipranks.com/news/blurbs/lifesci-capital-keeps-their-buy-rating-on-bellus-health-blu?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Mar 2023 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Apr 2022 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.